AR and prostate cancer: To determine the effects of HDACi on prostate cancer cell migration, we performed migration assays in AR-positive LNCaP cells using several concentrations of SAHA (0.1, 0.25, 0.5, 1, 2 and 4 μM), a commercially available HDACi.